Category: LUNG CANCER MARKER | Code: A3102
EGFR Mutation Express(4 Exons)
Function
The EGFR mutation test is useful for determining the suitability of tyrosine kinase inhibitor (TKI) therapy in patients with non-small cell lung cancer (NSCLC). EGFR mutations are present in 38-43% of lung adenocarcinomas, and determine response to drugs such as erlotinib, afatinib, and gefitinib. This assay includes mutations at exon points 18-21, including the T790M mutation that can predict resistance to TKI therapy.
| Test Schedule | Estimated Test Result | Container | Substance | Stability |
|---|---|---|---|---|
| Monday - Friday | 2 days | - | FFPE Block, Rinse | Room temperature |
Condition
The block must contain tumor cells
Method
High Resolution Melting (HRM) PCR dan Restriction Fragment Length Polymorphism (RFLP)
